ReWalk Robotics Reports First Quarter

ReWalk Robotics Reports First Quarter

2018 Financial Results

ReWalk shareholders approve $20 million investment agreement with Timwell Corporation Limited -

Total revenue of $1.6 million during the first quarter of 2018 -

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, May 10, 2018 -

ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial results for

the three months ended March 31, 2018.

Highlights of and subsequent to the first quarter include:

"We look forward to continued

momentum in the business as we advance our top priorities for the year: executing on our joint venture to bring our products to

market in China, working to expand reimbursement coverage in the U.S. and Germany, and advancing the clinical studies for the Restore

soft-suit exoskeleton with a targeted launch in the first half of 2019," stated Larry Jasinski, Chief Executive Officer of

First Quarter 2018 Financial

Total revenue was $1.6 million for

the first quarter of 2018, compared to $1.5 million in the fourth quarter of 2017 and $2.5 million during the prior year quarter.

23 ReWalk systems were placed during the first quarter of 2018, compared to 23 ReWalk systems placed in the prior quarter and 37

systems in the prior year period. Fourteen systems were placed in the U.S., seven were placed in our direct markets in Europe,

and two were placed in other markets. During the first quarter of 2018, 8 units were purchased for the U.S. Department of Veteran's

Affairs to support their ongoing clinical study.

Gross margin improved to 43% during

the first quarter of 2018 compared to 42% in the first quarter of 2017, primarily attributable to sales mix and lower product costs.

Total operating expenses in the first

quarter of 2018 were $6.5 million compared to $6.7 million in the prior year period.

Net loss was $6.3 million for the first

quarter of 2018 compared to a net loss of $6.4 million in the first quarter of 2017. Non-GAAP net loss for the first quarter was

$5.4 million compared with a non-GAAP net loss of $5.3 million in the first quarter of 2017. A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

As of March 31, 2018, ReWalk had $8.8

million in cash on its balance sheet, excluding $5 million in gross proceeds upon closing of the Timwell Corporation Limited investment.

ReWalk management will host its first

quarter 2018 conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 1175903.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures

and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk's mission is to fundamentally change

the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies.

Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel.

Forward-Looking Statements

In addition to historical information, this press release contains

forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the

U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include

projections regarding ReWalk's future performance and, in some cases, may be identified by words like "anticipate,"

"assume," "believe," "continue," "could," "estimate," "expect,"

"intend," "may," "plan," "potential," "predict," "project,"

"future," "will," "should," "would," "seek" and similar terms or phrases.

The forward-looking statements contained in this press release are based on management's current expectations, which are

subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's

control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking

statements include, among others: ReWalk's expectations regarding future growth, including its ability to increase sales

in its existing geographic markets, and to expand to new markets and achieve its planned expense reductions; the conclusion of

ReWalk's management and the previous opinion of ReWalk's auditors, that there are substantial doubts as to ReWalk's

ability to continue as a going concern; ReWalk's ability to maintain and grow its reputation and the market acceptance of

its products; ReWalk's ability to achieve reimbursement from third-party payors for its products; ReWalk's expectations

as to its clinical research program and clinical results; ReWalk's expectations as to the results of, and the Food and Drug

Administration's potential regulatory developments with respect to, ReWalk's mandatory post-market 522 surveillance

study; the outcome of ongoing shareholder class action litigation relating to ReWalk's initial public offering; ReWalk's

ability to repay its secured indebtedness; ReWalk's ability to improve its products and develop new products; ReWalk's

ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights

of others; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's ability to secure capital from its

equity and debt financings in light of limitations under its Form S-3, the price range of its ordinary shares and conditions in

the financial markets, and the risk that such financings may dilute ReWalk's shareholders or restrict its business; ReWalk's

ability to use effectively the proceeds of offerings of securities; ReWalk's ability to maintain relationships with existing

customers and develop relationships with new customers; the impact of the market price of ReWalk's ordinary shares on the

determination of whether ReWalk is a passive foreign investment company; ReWalk's ability to regain compliance with the continued

listing requirements of the NASDAQ Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk's

compliance with medical device reporting regulations to report adverse events involving its products and the potential impact of

such adverse events on ReWalk's ability to market and sell its products; the risk of substantial dilution resulting from

the issuance to Timwell; the significant voting power and de facto voting control Timwell may acquire; the risk that the remaining

Timwell issuances will fail to close and the China joint venture will not form; and other factors discussed under the heading "Risk

Factors" in ReWalk's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC and

other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks

only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained

herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk

undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are

prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of

non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers

to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three months ended March 31, 2018 and 2017, non-GAAP

net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense, (ii) depreciation and (iii) non-cash

Because of varying available valuation

methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash expenses,

ReWalk believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense, depreciation

and non-cash financial (income) expenses allows for more meaningful comparisons between operating results from period to period.

Each of the Company's non-GAAP financial measures is an important tool for financial and operational decision-making and

for the Company's evaluation of its operating results over different periods of time. The non-GAAP financial data are not

measures of the Company's financial performance under U.S. GAAP, and should not be considered as alternatives to operating

loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide

information that is directly comparable to that provided by other companies in ReWalk's industry, as other companies in the

industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition,

there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance

with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material

impact on the Company's reported financial results. Further, share-based compensation expense has been, and will continue

to be for the foreseeable future, a significant recurring expense in the Company's business and an important part of the